Selecta Biosciences Inc. (SELB)
0.88
-0.08 (-8.12%)
At close: Nov 13, 2023, 9:00 PM
-8.12% (1D)
| Bid | n/a |
| Market Cap | 135.2M |
| Revenue (ttm) | 34.53M |
| Net Income (ttm) | -40.25M |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | -3.0386206896551724 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 2,763,021 |
| Avg. Volume (20D) | 634,418 |
| Open | 0.89 |
| Previous Close | 0.96 |
| Day's Range | 0.81 - 0.94 |
| 52-Week Range | 0.79 - 1.99 |
| Beta | 0.83 |
About SELB
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the t...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2016
Employees 64
Stock Exchange NASDAQ
Ticker Symbol SELB
Website https://selectabio.com